Back to Search Start Over

Omentum preservation versus complete omentectomy in gastrectomy for gastric cancer (OMEGA trial): study protocol for a randomized controlled trial.

Authors :
Keywani K
Eshuis WJ
Borgstein ABJ
van Det MJ
van Duijvendijk P
van Etten B
Grimminger PP
Heisterkamp J
Lagarde SM
Luyer MDP
Markar SR
Meijer SL
Pierie JPEN
Roviello F
Ruurda JP
van Sandick JW
Sosef M
Witteman BPL
de Steur WO
Lissenberg-Witte BI
van Berge Henegouwen MI
Gisbertz SS
Source :
Trials [Trials] 2024 Sep 04; Vol. 25 (1), pp. 588. Date of Electronic Publication: 2024 Sep 04.
Publication Year :
2024

Abstract

Background: Potentially curative therapy for locally advanced gastric cancer consists of gastrectomy, usually in combination with perioperative chemotherapy. An oncological resection includes a radical (R0) gastrectomy and modified D2 lymphadenectomy; generally, a total omentectomy is also performed, to ensure the removal of possible microscopic disease. However, the omentum functions as a regulator of regional immune responses to prevent infections and prevents adhesions which could lead to bowel obstructions. Evidence supporting a survival benefit of routine complete omentectomy during gastrectomy is lacking.<br />Methods: OMEGA is a randomized controlled, open, parallel, non-inferiority, multicenter trial. Eligible patients are operable (ASA < 4) and have resectable (≦ cT4aN3bM0) primary gastric cancer. Patients will be 1:1 randomized between (sub)total gastrectomy with omentum preservation distal of the gastroepiploic vessels versus complete omentectomy. For a power of 80%, the target sample size is 654 patients. The primary objective is to investigate whether omentum preservation in gastrectomy for cancer is non-inferior to complete omentectomy in terms of 3-year overall survival. Secondary endpoints include intra- and postoperative outcomes, such as blood loss, operative time, hospital stay, readmission rate, quality of life, disease-free survival, and cost-effectiveness.<br />Discussion: The OMEGA trial investigates if omentum preservation during gastrectomy for gastric cancer is non-inferior to complete omentectomy in terms of 3-year overall survival, with non-inferiority being determined based on results from both the intention-to-treat and the per-protocol analyses. The OMEGA trial will elucidate whether routine complete omentectomy could be omitted, potentially reducing overtreatment.<br />Trial Registration: ClinicalTrials.gov NCT05180864. Registered on 6 <superscript>th</superscript> January 2022.<br /> (© 2024. The Author(s).)

Details

Language :
English
ISSN :
1745-6215
Volume :
25
Issue :
1
Database :
MEDLINE
Journal :
Trials
Publication Type :
Academic Journal
Accession number :
39232781
Full Text :
https://doi.org/10.1186/s13063-024-08396-z